This database contains 14 studies, archived under the term: "electroencephalography"
Click here to filter this large number of results.
Wavelet coherence model for diagnosis of Alzheimer disease
This article presents a wavelet coherence investigation of electroencephalograph (EEG) readings acquired from patients with Alzheimer disease (AD) and healthy controls. Pairwise electrode wavelet coherence is calculated over each frequency band (delta, theta, alpha, and beta). For comparing the synchronization fraction of 2 EEG signals, a wavelet coherence fraction is proposed which is defined as […]
Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease
Farlow, Martin,
Arnold, Steven E.,
van Dyck, Christopher H.,
Aisen, Paul S,
Snider, B. Joy,
Porsteinsson, Anton P.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon,
Sethuraman, Gopalan,
Demattos, Ronald B.,
Mohs, Richard,
Paul, Steven M.,
Siemers, Eric R.
Objectives: To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of 12 weekly infusions of solanezumab, an anti-β-amyloid (Aβ) antibody, in patients with mild-to-moderate Alzheimer’s disease. Cognitive measures were also obtained.; Methods: In this phase 2, randomized, double-blind, placebo-controlled clinical trial, 52 patients with Alzheimer’s disease received placebo or antibody (100 mg every 4 weeks, 100 […]
Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial
Scheltens, Philip,
Twisk, Jos W.R.,
Blesa, Rafael,
Scarpini, Elio,
von Arnim, Christine A. F.,
Bongers, Anke,
Harrison, John,
Swinkels, Sophie H. N.,
Stam, Cornelis J.,
de Waal, Hanneke,
Wurtman, Richard J.,
Wieggers, Rico L.,
Vellas, Bruno,
Kamphuis, Patrick J. G. H.
Souvenaid aims to improve synapse formation and function. An earlier study in patients with Alzheimer’s disease (AD) showed that Souvenaid increased memory performance after 12 weeks in drug-naïve patients with mild AD. The Souvenir II study was a 24-week, randomized, controlled, double-blind, parallel-group, multi-country trial to confirm and extend previous findings in drug-naïve patients with […]
Persistence of the effects of Cerebrolysin on cognition and qEEG slowing in vascular dementia patients: results of a 3-month extension study
Muresanu, Dafin F.,
Alvarez, X. Anton,
Moessler, Herbert,
Novak, Philipp H.,
Stan, Adina,
Buzoianu, Anca,
Bajenaru, Ovidiu,
Popescu, Bogdan O.
The maintenance of the effects of Cerebrolysin, a peptidergic compound with neurotrophic activity, on cognitive performance and qEEG activity was investigated through a 12-week, open-label extension of a 4-week, randomised, placebo-controlled pilot study. Thirty-three out of 41 patients with mild-to-moderate severe probable vascular dementia (VaD) according to NINDS-AIREN participating in the double-blind phase of the […]
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, Claudio,
Frisoni, Giovanni B.,
Del Percio, Claudio,
Zanetti, Orazio,
Bonomini, Cristina,
Cassetta, Emanuele,
Pasqualetti, Patrizio,
Miniussi, Carlo,
De Rosas, Mario,
Valenzano, Anna,
Cibelli, Giuseppe,
Eusebi, Fabrizio,
Rossini, Paolo M.
Objective: Non-steroidal anti-inflammatory drugs such as ibuprofen have a protective role on risk of Alzheimer’s disease (AD). Here we evaluated the hypothesis that long-term ibuprofen treatment affects cortical sources of resting electroencephalographic (EEG) rhythms in mild AD patients.; Methods: Twenty-three AD patients (13 treated AD IBUPROFEN; 10 untreated AD PLACEBO) were enrolled. Resting EEG data […]
A phase I trial of deep brain stimulation of memory circuits in Alzheimer’s disease
Laxton, Adrian W.,
Tang-Wai, David F.,
McAndrews, Mary Pat,
Zumsteg, Dominik,
Wennberg, Richard,
Keren, Ron,
Wherrett, John,
Naglie, Gary,
Hamani, Clement,
Smith, Gwenn S.,
Lozano, Andres M.
Objective: Alzheimer disease (AD) is characterized by functional impairment in the neural elements and circuits underlying cognitive and memory functions. We hypothesized that fornix/hypothalamus deep brain stimulation (DBS) could modulate neurophysiological activity in these pathological circuits and possibly produce clinical benefits.; Methods: We conducted a phase I trial in 6 patients with mild AD receiving […]
Autoimmune dementia: clinical course and predictors of immunotherapy response
Flanagan, Eoin P.,
McKeon, Andrew,
Lennon, Vanda A.,
Boeve, Bradley F.,
Trenerry, Max R.,
Tan, K. Meng,
Drubach, Daniel A.,
Josephs, Keith A.,
Britton, Jeffrey W.,
Mandrekar, Jayawant N.,
Lowe, Val,
Parisi, Joseph E.,
Pittock, Sean J.
Objective: To define the diagnostic characteristics and predictors of treatment response in patients with suspected autoimmune dementia.; Patients and Methods: Between January 1, 2002, and January 1, 2009, 72 consecutive patients received immunotherapy for suspected autoimmune dementia. Their baseline clinical, radiologic, and serologic characteristics were reviewed and compared between patients who were responsive to immunotherapy […]